COVID-19 pneumonia. Confirmed diagnosis of COVID-19
Conditions
Interventions
Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal drug three times a day after meals. The herbal capsule
Sponsors
Zarsan Salamat Company
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients infected with COVID-19 Confirmation of coronavirus infection with chest CT scan and PCR test Age 20 to 70 years Ability to take oral medication Personal desire to participate in the project and the signing of a written consent
Exclusion criteria
Exclusion criteria: Patients with severe dyspnea Patients with reduced level of consciousness or need hospitalization in intensive care units Patients with swallowing disorders or possibility of aspiration of food or unable to take the drug orally Patients with respiratory failure require mechanical ventilation Patients with resistant hypoxemia Patients with organ transplantation; malignant disease; treated with corticosteroids or chemotherapy Patients with uncontrolled blood pressure, uncontrolled diabetes, cardiovascular disease and underlying respiratory disease Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood oxygen saturation. Timepoint: At beginning and regularly during study. Method of measurement: Pulse Oximeter.;Lung inflammation. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.;Cough. Timepoint: Night and day during the study. Method of measurement: Questionnaire.;Shortness of breath. Timepoint: Daily during the study. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory Rate. Timepoint: At beginning and regularly during study. Method of measurement: Respiratory Count per minute.;C-reactive protein. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;CBC. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ESR. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;BUN. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Creatinine. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;K. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Na. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Body temprature. Timepoint: At beginning and daily up to end of the study. Method of measurement: Thermometer.;ALT. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;AST. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ALK. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfsaneh Kafash
Sabzevar University of Medical Sciences
Outcome results
None listed